Published in Nat Med on February 09, 2014
Malaria medicines: a glass half full? Nat Rev Drug Discov (2015) 2.53
New developments in anti-malarial target candidate and product profiles. Malar J (2017) 1.50
Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe (2015) 1.07
KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. Antimicrob Agents Chemother (2013) 1.03
Characterization of metabolically quiescent Leishmania parasites in murine lesions using heavy water labeling. PLoS Pathog (2015) 0.94
Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax. Pathog Glob Health (2015) 0.90
No more monkeying around: primate malaria model systems are key to understanding Plasmodium vivax liver-stage biology, hypnozoites, and relapses. Front Microbiol (2015) 0.90
Metabolomics in the fight against malaria. Mem Inst Oswaldo Cruz (2014) 0.87
Plasmodium falciparum full life cycle and Plasmodium ovale liver stages in humanized mice. Nat Commun (2015) 0.86
Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages. ACS Med Chem Lett (2014) 0.84
Malarial liver parasites awaken in culture. Nat Med (2014) 0.82
Malaria vaccines: identifying Plasmodium falciparum liver-stage targets. Front Microbiol (2015) 0.81
New insight-guided approaches to detect, cure, prevent and eliminate malaria. Protoplasma (2014) 0.81
PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites. Antimicrob Agents Chemother (2016) 0.81
Malaria vaccine clinical trials: what's on the horizon. Curr Opin Immunol (2015) 0.80
Development of diaminoquinazoline histone lysine methyltransferase inhibitors as potent blood-stage antimalarial compounds. ChemMedChem (2014) 0.80
Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. ACS Cent Sci (2016) 0.80
Key Knowledge Gaps for Plasmodium vivax Control and Elimination. Am J Trop Med Hyg (2016) 0.79
Microphysical space of a liver sinusoid device enables simplified long-term maintenance of chimeric mouse-expanded human hepatocytes. Biomed Microdevices (2014) 0.79
Plasmodium cynomolgi infections in rhesus macaques display clinical and parasitological features pertinent to modelling vivax malaria pathology and relapse infections. Malar J (2016) 0.79
Plasmodium falciparum: multifaceted resistance to artemisinins. Malar J (2016) 0.78
The suitability of laboratory-bred Anopheles cracens for the production of Plasmodium vivax sporozoites. Malar J (2015) 0.78
Phenotypic Screens in Antimalarial Drug Discovery. Trends Parasitol (2016) 0.78
Histone methyltransferase inhibitors are orally bioavailable, fast-acting molecules with activity against different species causing malaria in humans. Antimicrob Agents Chemother (2014) 0.78
Identification of 2,4-diamino-6,7-dimethoxyquinoline derivatives as G9a inhibitors†Electronic supplementary information (ESI) available. See DOI: 10.1039/c4md00274a. Medchemcomm (2014) 0.77
Delayed Onset of Symptoms and Atovaquone-Proguanil Chemoprophylaxis Breakthrough by Plasmodium malariae in the Absence of Mutation at Codon 268 of pmcytb. PLoS Negl Trop Dis (2015) 0.77
Epigenetic Regulation of Virulence Gene Expression in Parasitic Protozoa. Cell Host Microbe (2016) 0.76
Diagnosis and Treatment of Plasmodium vivax Malaria. Am J Trop Med Hyg (2016) 0.75
Plasmodium falciparum PfSET7: enzymatic characterization and cellular localization of a novel protein methyltransferase in sporozoite, liver and erythrocytic stage parasites. Sci Rep (2016) 0.75
Selective sweep suggests transcriptional regulation may underlie Plasmodium vivax resilience to malaria control measures in Cambodia. Proc Natl Acad Sci U S A (2016) 0.75
Towards a Humanized Mouse Model of Liver Stage Malaria Using Ectopic Artificial Livers. Sci Rep (2017) 0.75
Current therapies and future possibilities for drug development against liver-stage malaria. J Clin Invest (2016) 0.75
Implications of Plasmodium vivax Biology for Control, Elimination, and Research. Am J Trop Med Hyg (2016) 0.75
Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection. Virology (2016) 0.75
Malaria modeling: In vitro stem cells vs in vivo models. World J Stem Cells (2016) 0.75
Laser capture microdissection enables transcriptomic analysis of dividing and quiescent liver stages of Plasmodium relapsing species. Cell Microbiol (2017) 0.75
Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A (2002) 4.52
Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science (2006) 4.20
Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J (2011) 4.00
A strain of Plasmodium vivax characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. Trans R Soc Trop Med Hyg (1976) 3.19
Genome-wide analysis of heterochromatin associates clonally variant gene regulation with perinuclear repressive centers in malaria parasites. Cell Host Microbe (2009) 2.95
Hepatocyte function and extracellular matrix geometry: long-term culture in a sandwich configuration. FASEB J (1989) 2.89
The silent path to thousands of merozoites: the Plasmodium liver stage. Nat Rev Microbiol (2006) 2.83
Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol (2010) 2.75
Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat Med (2002) 2.46
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin (2010) 2.36
Support of cultured hepatocytes by a laminin-rich gel. Evidence for a functionally significant subendothelial matrix in normal rat liver. J Clin Invest (1987) 2.28
Demonstration of a persisting exo-erythrocytic cycle in Plasmodium cynomolgi and its bearing on the production of relapses. Br Med J (1948) 2.21
A pre-emptive strike against malaria's stealthy hepatic forms. Nat Rev Drug Discov (2009) 1.77
The Apicomplexan AP2 family: integral factors regulating Plasmodium development. Mol Biochem Parasitol (2010) 1.74
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem (2010) 1.73
Long-term co-cultures of adult human hepatocytes with rat liver epithelial cells: modulation of albumin secretion and accumulation of extracellular material. Hepatology (1984) 1.62
Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One (2011) 1.60
Relapses in primate malaria: discovery of two populations of exoerythrocytic stages. Preliminary note. Br Med J (1980) 1.34
The hypnozoite and relapse in primate malaria. Clin Microbiol Rev (1992) 1.34
Cultivation of the liver forms of Plasmodium vivax in human hepatocytes. Nature (1984) 1.33
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab (2007) 1.22
General review on in vitro hepatocyte models and their applications. Methods Mol Biol (2010) 1.17
Efficient restricted gene expression in beta cells by lentivirus-mediated gene transfer into pancreatic stem/progenitor cells. Diabetologia (2005) 1.17
Plasmodium cynomolgi infections in the rhesus monkey. Am J Trop Med Hyg (1982) 1.13
In vitro culture of two populations (dividing and nondividing) of exoerythrocytic parasites of Plasmodium vivax. Am J Trop Med Hyg (1985) 1.08
Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS One (2010) 1.08
Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. Proc Natl Acad Sci U S A (2012) 1.04
In vitro culture of exoerythrocytic parasites of the North Korean strain of Plasmodium vivax in hepatoma cells. Am J Trop Med Hyg (1986) 1.02
Observations on early and late post-sporozoite tissue stages in primate malaria. I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24 hours after infection. Am J Trop Med Hyg (1982) 1.00
[Observation on hypnozoite of different isolates of Plasmodium vivax in cultured materials]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (1995) 0.98
Transgenic fluorescent Plasmodium cynomolgi liver stages enable live imaging and purification of Malaria hypnozoite-forms. PLoS One (2013) 0.91
Extended primary culture of human hepatocytes in a collagen gel sandwich system. In Vitro Cell Dev Biol Anim (1997) 0.88
Statistical model to evaluate in vivo activities of antimalarial drugs in a Plasmodium cynomolgi-macaque model for Plasmodium vivax malaria. Antimicrob Agents Chemother (2008) 0.88
Localization of circumsporozoite antigen in exoerythrocytic schizonts of Plasmodium cynomolgi. Am J Trop Med Hyg (1989) 0.81
Demonstration of in vitro cultured exoerythrocytic schizonts and hypnozoites of Plasmodium vivax (southern China isolate) by an immunoperoxidase antibody technique. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (1995) 0.75
Targeting Plasmodium PI(4)K to eliminate malaria. Nature (2013) 2.49
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother (2014) 1.01
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother (2014) 0.90
Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model. Antimicrob Agents Chemother (2014) 0.83
Crystal structure of Plasmodium knowlesi apical membrane antigen 1 and its complex with an invasion-inhibitory monoclonal antibody. PLoS One (2015) 0.82
Low levels of polymorphisms and no evidence for diversifying selection on the Plasmodium knowlesi Apical Membrane Antigen 1 gene. PLoS One (2015) 0.82
Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation. PLoS One (2016) 0.75
Semi-high-throughput detection of Plasmodium falciparum and Plasmodium vivax oocysts in mosquitoes using bead-beating followed by circumsporozoite ELISA and quantitative PCR. Malar J (2017) 0.75
Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana. PLoS One (2017) 0.75